Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharvaris N.V.

14.97
-0.1250-0.83%
Volume:17.01K
Turnover:257.48K
Market Cap:815.49M
PE:-5.82
High:15.38
Open:15.10
Low:14.70
Close:15.09
Loading ...

Company Profile

Company Name:
Pharvaris N.V.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
108
Office Location:
Emmy Noetherweg 2,Leiden,Zuid-Holland,Netherlands
Zip Code:
2333 BK
Fax:
- -
Introduction:
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Directors

Name
Position
Berndt Modig
Chief Executive Officer and Executive Director
Anne Marie de Jonge Schuermans
Non-Executive Director
David Meeker
Non-Executive Director
Elisabeth Bjork
Non-Executive Director
Hans Schikan
Non-Executive Director
Robert Glassman
Non-Executive Director
Viviane Monges
Non-Executive Director

Shareholders

Name
Position
Berndt Modig
Chief Executive Officer and Executive Director
Jochen Knolle
Chief Scientific Officer and Chief Operating Officer
Anna Nijdam
Head of Finance and Principal Accounting Officer
Anne Lesage
Chief Early Development Officer
Annick Deschoolmeester
Chief Human Resources Officer
Joan Schmidt
Chief Legal Officer
Morgan Conn
Chief Business Officer
Peng Lu
Chief Medical Officer
Wim Souverijns
Chief Community Engagement and Commercial Officer